Lauren Amable, Ph.D.
Dr. Lauren Amable's research focuses on using metallomics to study the role that trace metals and elements play in the maintenance of health and the prevention of disease. She has developed the methodology to capture more than 16 metals in a variety of biospecimens using inductively coupled plasma mass spectrometry. The metallomic assays give insight into an individual's nutritional health as well as their harmful metal exposure status. Using metallomics, researchers can unlock new avenues of research and understanding into how metals play a role in the maintenance of health, the prevention of disease, and the response to therapy.
Dr. Amable earned her Ph.D. in basic medical sciences with a focus on biochemistry and molecular biology from the University of South Alabama in 2008. For her postdoctoral training, she studied under Dr. Eddie Reed at the Mitchell Cancer Institute investigating the molecular mechanism of resistance of the chemotherapy drug cisplatin and why some patients respond while others do not. She followed Dr. Reed to the National Institute on Minority Health and Health Disparities, where she became his staff scientist.
- Amable, L. (2016). Cisplatin resistance and opportunities for precision medicine. Pharmacological Research, 106, 27–36.
- Ho, W. S., Feldman, M. J., Maric, D., Amable, L., Hall, M. D., Feldman, G. M., … Heiss, J. D. (2016). PP2A inhibition with LB100 enhances cisplatin cytotoxicity and overcomes cisplatin resistance in medulloblastoma cells. Oncotarget, 7, 12447–12463. doi: 10.18632/oncotarget.6970.
- Amable, L., Fain, J., Gavin, E., & Reed, E. (2014). Gli1 contributes to cellular resistance to cisplatin through altered cellular accumulation of the drug. Oncology Reports, 32, 469–474.